Investors aiming for above-average returns often turn to the practice of stock picking. Skillful choices in individual stocks can be a catalyst for substantial wealth growth.
As of close of business last night, Arcutis Biotherapeutics Inc’s stock clocked out at $29.02, down -1.53% from its previous closing price of $29.47. In other words, the price has decreased by -$1.53 from its previous closing price. On the day, 1.73 million shares were traded. ARQT stock price reached its highest trading level at $29.505 during the session, while it also had its lowest trading level at $28.3.
Ratios:
To gain a deeper understanding of ARQT’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 3.28 and its Current Ratio is at 3.50. In the meantime, Its Debt-to-Equity ratio is 0.72 whereas as Long-Term Debt/Eq ratio is at 0.71.
Upgrades & Downgrades
In the most recent recommendation for this company, Goldman on July 25, 2025, initiated with a Neutral rating and assigned the stock a target price of $18.
On December 30, 2024, H.C. Wainwright started tracking the stock assigning a Buy rating and target price of $19.
On August 28, 2024, Jefferies started tracking the stock assigning a Buy rating and target price of $15.Jefferies initiated its Buy rating on August 28, 2024, with a $15 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Dec 01 ’25 when Matsuda Masaru sold 1,657 shares for $30.23 per share. The transaction valued at 50,091 led to the insider holds 150,641 shares of the business.
Welgus Howard G. sold 10,000 shares of ARQT for $302,133 on Dec 01 ’25. The Director now owns 79,744 shares after completing the transaction at $30.21 per share. On Dec 01 ’25, another insider, Howard Welgus, who serves as the Director of the company, bought 10,000 shares for $30.21 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ARQT now has a Market Capitalization of 3554723584 and an Enterprise Value of 3477429504. For the stock, the TTM Price-to-Sale (P/S) ratio is 11.18 while its Price-to-Book (P/B) ratio in mrq is 22.08. Its current Enterprise Value per Revenue stands at 10.938 whereas that against EBITDA is -104.777.
Stock Price History:
The Beta on a monthly basis for ARQT is 1.71, which has changed by 1.1717024 over the last 52 weeks, in comparison to a change of 0.13613915 over the same period for the S&P500. Over the past 52 weeks, ARQT has reached a high of $31.77, while it has fallen to a 52-week low of $11.13. The 50-Day Moving Average of the stock is 15.85%, while the 200-Day Moving Average is calculated to be 65.29%.
Shares Statistics:
It appears that ARQT traded 2.33M shares on average per day over the past three months and 1830030 shares per day over the past ten days. A total of 120.29M shares are outstanding, with a floating share count of 107.63M. Insiders hold about 12.13% of the company’s shares, while institutions hold 96.66% stake in the company. Shares short for ARQT as of 1764288000 were 12059791 with a Short Ratio of 5.18, compared to 1761868800 on 13479227. Therefore, it implies a Short% of Shares Outstanding of 12059791 and a Short% of Float of 12.100001.
Earnings Estimates
The market rating for Arcutis Biotherapeutics Inc (ARQT) is a result of the insights provided by 7.0 analysts actively involved in the assessment.The consensus estimate for the next quarter is $0.03, with high estimates of $0.12 and low estimates of -$0.02.
Analysts are recommending an EPS of between $0.15 and -$0.31 for the fiscal current year, implying an average EPS of -$0.15. EPS for the following year is $0.45, with 7.0 analysts recommending between $0.78 and $0.25.
Revenue Estimates
In. The current quarter, 6 analysts expect revenue to total $109.83M. It ranges from a high estimate of $112.6M to a low estimate of $107M. As of. The current estimate, Arcutis Biotherapeutics Inc’s year-ago sales were $71.36MFor the next quarter, 6 analysts are estimating revenue of $98.23M. There is a high estimate of $102.31M for the next quarter, whereas the lowest estimate is $94.6M.
A total of 8 analysts have provided revenue estimates for ARQT’s current fiscal year. The highest revenue estimate was $361.3M, while the lowest revenue estimate was $353.6M, resulting in an average revenue estimate of $357.45M. In the same quarter a year ago, actual revenue was $196.54MBased on 8 analysts’ estimates, the company’s revenue will be $467.32M in the next fiscal year. The high estimate is $470.1M and the low estimate is $462M.
